New hope for advanced HER2 cancers? early trial of ZV0203 begins
Disease control
ENROLLING_BY_INVITATION
This early-phase study tests a new drug called ZV0203 in about 36 adults with advanced HER2-positive solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look at how the drug …
Phase: PHASE1 • Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:48 UTC